Evidence map›Paper›PMID 37463955›Full record

ArticleScientific reports2023

Effective SARS-CoV-2 replication of monolayers of intestinal epithelial cells differentiated from human induced pluripotent stem cells.

Shohei Minami, Naomi Matsumoto, Hiroko Omori, Yutaka Nakamura, Shigeyuki Tamiya, Ryotaro Nouda, Jeffery A Nurdin, Moeko Yamasaki, Tomohiro Kotaki, Yuta Kanai and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Shohei MinamiDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Naomi MatsumotoDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Hiroko OmoriCore Instrumentation Facility, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Yutaka NakamuraDepartment of Microbiology and Immunology, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, 640-8156, Japan.
Shigeyuki TamiyaDepartment of Microbiology and Immunology, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, 640-8156, Japan.
Ryotaro NoudaDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Jeffery A NurdinDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Moeko YamasakiDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Tomohiro KotakiDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Yuta KanaiDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Toru OkamotoInstitute for Advanced Co-creation Studies, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.
Taro TachibanaCell Engineering Corporation, Osaka, 532-0011, Japan.
Hiroshi UshijimaDivision of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, 173-8610, Japan.
Takeshi KobayashiDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan. tkobayashi@biken.osaka-u.ac.jp.
Shintaro SatoDepartment of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan. shintas@wakayama-med.ac.jp.
The University of Osaka · JPWakayama Medical University · JPNihon University · JPOsaka International Cancer Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe acute respiratory symptoms in humans. Controlling the coronavirus disease pandemic is a worldwide priority. The number of SARS-CoV-2 studies has dramatically increased, and the requirement for analytical tools is higher than ever. Here, we propose monolayered-intestinal epithelial cells (IECs) derived from human induced pluripotent stem cells (iPSCs) instead of three-dimensional cultured intestinal organoids as a suitable tool to study SARS-CoV-2 infection. Differentiated IEC monolayers express high levels of angiotensin-converting enzyme 2 and transmembrane protease serine 2 (TMPRSS2), host factors essential for SARS-CoV-2 infection. SARS-CoV-2 efficiently grows in IEC monolayers. Using this propagation system, we confirm that TMPRSS2 inhibition blocked SARS-CoV-2 infection in IECs. Hence, our iPSC-derived IEC monolayers are suitable for SARS-CoV-2 research under physiologically relevant conditions.

Indexed as

COVID-19Induced Pluripotent Stem CellsEpithelial CellsHumansIntestinesSARS-CoV-2

Identifiers

PMID37463955
PMCPMC10354114
OpenAlexW4384664481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.